Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients

Roche's enicepatide has successfully met both primary endpoints in a Phase II trial for Type 2 diabetes and obesity, achieving a mean HbA1c reduction of 2.65% at the highest dose of 24 mg over 48 weeks. In patients with poor baseline glycemic control, the drug led to a significant HbA1c reduction of 4.13%. Additionally, 90% of patients in the 24 mg group met the glycemic target of ≤6.5% HbA1c, and the treatment resulted in a mean weight loss of 15.5% without plateauing. The safety profile of enicepatide was consistent with the incretin class, showing low discontinuation rates and no new safety concerns.